Tocilizumab vs. baricitinib in hospitalized severe COVID-19 patients: results from a real-world cohort.

Authors:
Karolyi M; Gruebl A; Omid S; Saak M; Pawelka E and 12 more

Journal:
Infection

Publication Year: 2022

DOI:
10.1007/s15010-022-01915-7

PMCID:
PMC9461450

PMID:
36083403

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Infection

Abbreviation: Infection

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Allergy and Immunology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
A case of occupational transmission of mpox.
Migaud P; Hosmann K; Drauz D and 3 more (2023) - Transparency Score: 3/6
An appeal for strengthening genomic pathogen surveillance to improve pandemic preparedness and infe…
Salzberger B; Mellmann A; Bludau A and 19 more (2023) - Transparency Score: 3/6
Antibody responses after sequential vaccination with PCV13 and PPSV23 in kidney transplant recipien…
Mülling N; van de Sand L; Völk K and 8 more (2023) - Transparency Score: 3/6
Blazing the trail for innovative tuberculosis diagnostics.
Yerlikaya S; Broger T; Isaacs C and 6 more (2023) - Transparency Score: 3/6
Blood culture-negative infective endocarditis: are we looking hard enough?
Kirk F; Vaselli NM. (2023) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Competing interestsThe authors declare no competing interests. Conflict of interestAll authors declare that they do not have any conflicts of interest. Ethical approvalThe study was approved by the ethics committee of the capital city Vienna. Consent for publicationNot applicable. Competing interests The authors declare no competing interests. Conflict of interest All authors declare that they do not have any conflicts of interest."

Evidence found in paper:

"Funding This work did not receive any funding."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025